

**THE BRITISH ASSOCIATION OF  
UROLOGICAL SURGEONS**

**SECTION of ONCOLOGY**

**BAUS Cancer Registry  
Analyses of Minimum data set for Urological cancers  
January 1<sup>st</sup> – 31<sup>st</sup> December 2002**

**October 2003**

**MEMBERS OF THE EXECUTIVE COMMITTEE**

J B Anderson	D A Gillatt	D R Greene	D C Hanbury
A V Kaisary	R C Kocklebergh	G S McIntosh	R D Pocock
A W S Ritchie (co-opted)		P Whelan	

**PRODUCED FOR BAUS SECTION OF ONCOLOGY**  
**by**

**Mrs Sarah Fowler**  
**BAUS Cancer Registry Manager**

## CONTENTS

	Page Number
<b>Introduction</b>	<b>1</b>
<b>Results Summary &amp; Methods of analysis</b>	<b>2</b>
<b>A. Participants and Overall Figures</b> Charts 1 – 24	<b>3</b>
<b>B. Referral Source, Priority &amp; Time between Referral, First Consultation, Diagnosis and Definitive Treatment</b> Charts 25 – 56	<b>15</b>
<b>C. Histology</b> Charts 57 – 61	<b>33</b>
<b>D. Staging</b> Charts 62 – 74	<b>36</b>
<b>E. Initial Treatment Intention &amp; Management Type</b> Charts 75 – 88	<b>43</b>
<b>F. Tertiary Referrals</b> Chart 89	<b>51</b>
<b>G. Clinical Trial Status</b> Chart 90	<b>52</b>
<b>H. Completeness of Data</b> Charts 91 – 92	<b>53</b>
<b>Appendix</b> Listings of regional and district health authorities 1998 and 1999	<b>54</b>

## **Introduction**

On behalf of the Executive Committee of the Section of Oncology, I am pleased to introduce the analyses of the 2002 returns to the BAUS Cancer Registry. The number of newly presenting urological cancers reported has increased year on year and we now have a database of approximately 95,000 patients. Considering that we do not yet have any formal funding and that the data are submitted on a voluntary basis, this is a remarkable achievement on the part of the section's members (and many non-members).

The pivotal place of Sarah Fowler, our database manager, is acknowledged with huge appreciation.

Trends in urological oncology are commented on in the following sections. The introduction of the 'two week wait' has had an impact but the times to definitive treatment remain a problem.

For the first time we have included data on the clinical trial status of our patients.

The database can be seen as an epidemiological tool for your use and has been used as a basis for the following projects:-

- Clinical features of metastatic 'PSA negative' prostate cancer
- Management and outcome of patients with penile cancer
- Management and outcome of patients with muscle invasive bladder cancer
- Management of T1a carcinoma of the prostate
- Delays in the diagnosis of upper tract transitional cell cancers
- Waiting Times in Urology – Are we making progress?
- Follow up of renal cell cancer.
- Management and outcome of patients with Leydig cell testicular tumours
- Gene environment prostate cancer study
- Targeted PSA (TAPS) screening study for familial prostate cancer
- Individual and regional analyses by section members.

Applications to make use of the database are considered by the executive committee and forms for submission can be obtained from Jane Morrison at the BAUS office.

The executive is actively pursuing formal funding for the registry. Meanwhile, all members are urged to continue to submit their data and encourage colleagues to take part. Your support is essential and is gratefully acknowledged.

Alastair Ritchie  
Gloucester, October 2003

## AUDIT RESULTS SUMMARY January 1<sup>st</sup> – 31<sup>st</sup> December 2002

### Who took part?

444 consultant urologists from 166 hospital centres in England, Wales, Scotland, Northern Ireland and Eire provided data for this study submitting data on 28,351 newly presenting urological tumours from 1st January to 31<sup>st</sup> December 2002. Of the 444 consultants, 238 (54%) are members of the BAUS section of Oncology. These figures represent approximately 62% of the total UK tumours registered in 1999/2001 (45,787) (the most recent years available).

54% of the consultants (238/444) are members of the section of oncology and returned 67% of the data. 3.9% (1095/28351) were the private patients of 166 consultants.

### How were the data analysed?

Information obtained from consultants was entered into the computer database using unique identifying numbers for individual consultants or, if they preferred, a centre number. 8 centres returned data under a centre number only (28 consultants in total) and data from one other centre was returned under the centre number only for 6 out of 8 consultants.

Data could be returned either by completion of a pro forma for each patient (4,946 –17.5% of returns) or in electronic format using either an Access (Microsoft) database or “in-house” database (23,279 – 82% of returns) or a Psion database (Urocas) (76 –0.3% of returns) designed for the purpose. The pro formas were entered directly into an Access database, at which time validation comprising mainly of checks for duplicate entries and on dates and sex of patient could be carried out. 714 tumours were registered twice as a tertiary referral from another centre or another consultant in the same centre. They were only included once in all the analyses using the data from the primary site for all analyses except those relating to staging and treatment when the tertiary site data was used. In addition 7 benign tumours were registered but these have been excluded from all analyses.

The data presented here are a summary of the data received up to 8<sup>th</sup> September 2003 and relate to diagnoses made during the whole of 2002. The following data was included:

- a. Patients for who the date of diagnosis fell within the time period. (01/01/2002 to 31/12/2002). 27,624 registrations (97.4%).
- b. Patients for whom the date of diagnosis was either not included or the patient was a tertiary referral, but the referral date fell within the study period. (01/01/2002 to 31/12/2002) 484 registrations (1.7%).
- c. Patients for whom the diagnosis and referral dates were either not included or the patient was a tertiary referral, but the date of first consultation fell within the study period. (01/01/2002 to 31/12/2002). 243 (0.9%).

For the ranked charts (2,3,5 & 6) the individual consultant or centre identification numbers were removed and replaced with rank numbers starting at 1. A unique, confidential "Ranking Sheet" was prepared for each surgeon to enable them to identify their rank in every chart. For those charts where overall figures for the entire database are shown the ranking sheet displays the consultant's individual figures. No one else can identify the results of an individual consultant. The ranked comprise single bars, with in addition the 25, 50, and 75 percentiles and are ranked from left to right in the ascending order of the data item being measured. Where percentages are included figures have been rounded up to one decimal point. Unless otherwise stated all analyses represent the 2002 dataset.

A personal ranking sheet for each consultant was issued individually to go with this chartbook.

Sarah Fowler  
BAUS Cancer Registry (BCR) Manager, October 2003

## **A. Who took Part and Overall Figures**

We note a 6% increase in returns from 2001.

The number of prostate cancers has increased by 10.5% whereas there has been a small decrease in the number of bladder cancers reported.

As in 2000 and 2001, we have incorporated comparison with National Cancer Statistics from 1999/2001 – the latest years available. Chart 10 shows the registrations by region as compared to National Cancer statistics and the percentage change in BAUS returns by region from 2001 where possible. There were changes in the regional health authority boundaries between 1998 and 1999 making comparisons difficult. Listings of district health authorities within each region for 1998 and 1999 are shown in the Appendix. Once again there has been a large increase in returns from Scotland due primarily to the Scottish Urological Cancer Audit (SUCA) initiative.

The comparison with the national data suggests that our data are representative of the UK as a whole. However when comparing our data with that of the national data we should bear in mind the following:

- Our data are only being collected by urologists. We have no way of estimating the number of urological cancers that are not being seen or diagnosed by urologists. In the case of kidney cancer, it seems that a substantial number are never seen by a urologist.
- These data are being presented within nine months of the completion of the year of data collection and being compared to projected national figures from 1999/2001, which are the latest to be published.
- For the majority of participants, there is no specific funding for data collection and the analysis and presentation is entirely funded by the Section of Oncology.

### **Chart 1**

#### **BAUS - Register of Newly Presenting Urological Tumours**


**January 1st - December 31st 2002**

##### **Who took part**

- **444 Consultants from 166 Centres provided data on 28,351 newly presenting urological tumours.**
- **54% (238/444) Consultants are members of the Section of Oncology. These Consultants returned 67% of the data**
- **3.9% (1095/28351) were from the private patients of 166 Consultants**
- **Range of Consultants per Centre = 1 - 11, (Median 2)**
- **Median number of tumours per Consultant = 56, Range 1 - 262**
- **Median number of tumours per Centre = 150, Range 1 - 881**
- **82% (23279/28351) of the data were returned electronically**


## Chart 2

**Total Number of Newly Presenting Tumours Reported per Consultant**  
**Median: 56 (Interquartile Range 26 - 94)**



## Chart 3

**Total Number of Newly Presenting Tumours Reported per Centre**  
**Median: 150 (Interquartile Range 75 - 232)**



## Chart 4


**Number of Newly presenting Tumours by Organ per Consultant**  
**444 Consultants reported 28,351 Tumours**  
**Median Total per Consultant = 56**

Organ	Total Number Reported	Median per Consultant	Range
Prostate *	16580	30	0 – 224
Bladder	7611	14	0 – 66
Kidney	2270	3	0 – 39
Testis	984	2	0 – 23
Pelvis/Ureter	382	0	0 – 10
Penis	235	0	0 – 16
Urethra	25	0	0 – 1
Prostatic Urethra	19	0	0 - 2

\* Includes 101 registrations with High Grade PIN only

## Chart 5

**Total Number of Newly Presenting Tumours Reported per Consultant**  
**by Organ where n >=56 (i.e. the median reported per consultant)**




N.B. Excludes data returned by centres as a whole



## Chart 6

**Total Number of Newly Presenting Tumours Reported per Consultant  
by Organ where n >=56 (i.e. the median reported per consultant)  
Ranked by Prostate proportion**



N.B. Excludes data returned by centres as a whole

## Chart 7

### Overall Data by Organ

Organ	Number Recorded	Percentage of Total (28,351)	Mean Age at Diagnosis & Range	Males	Females
Prostate *	16580	58.5%	71.6; 20 – 102	16580	-
Bladder	7611	26.8%	71.4; 18 – 101	5631	1921
Kidney	2270	7.3%	64.8; 23 – 95	1420	835
Testis	984	3.5%	39.0; 16 – 89	984	-
Pelvis/Ureter	382	1.3%	70.0; 35 – 100	244	136
Penis	235	0.8%	66.1; 31 – 98	235	-
Urethra	25	0.09%	70.3; 49 – 89	21	4
Prostatic Urethra	19	0.07%	74.1; 54 – 92	19	-
Other	67	0.25%	66.5; 15 – 94	51	16
Not recorded	178	0.63%	70.2; 34 – 100	148	28

\* Includes 101 registrations with High Grade PIN only

## Chart 8

### Overall Data by Organ by Year

Organ	2002 Number Recorded	% of Total (28,351)	2001 Number Recorded	% of Total (26,746)	2000 Number Recorded	% of Total (24,343)	1999 Number Recorded	% of Total (19,009)	1998*** Number Recorded	% of Total (6,406)
Prostate	16580*	58.5%	15099 **	56.5%	12892	53.0%	9277	48.8%	2909	45.4%
Bladder	7611	26.8%	7730	28.9%	7549	31.0%	6584	34.6%	2440	38.1%
Kidney	2270	7.3%	2071	7.7%	2037	8.4%	1661	8.7%	515	8.0%
Testis	984	3.5%	963	3.6%	980	4.0%	838	4.4%	263	4.1%
Pelvis/Ureter	382	1.3%	358	1.3%	371	1.5%	281	1.5%	121	1.9%
Penis	235	0.8%	217	0.8%	221	0.9%	165	0.9%	73	1.1%
Urethra	25	0.09%	37	0.14%	33	0.14%	-	-	-	-
Prostatic Urethra	19	0.07%	19	0.07%	34	0.14%	-	-	-	-
Other	67	0.25%	62	0.23%	90	0.37%	120	0.6%	58	0.9%
Not recorded	178	0.63%	190	0.7%	136	0.6%	85	0.4%	27	0.4%

\* Includes 101 registrations with High Grade PIN only

\*\* Includes 109 registrations with High Grade PIN only

\*\*\* 6 months data only

## Chart 9

### “Other” Organ Tumours

The 67 “Others” included:

**16 Spermatic cord / Scrotum / Paratesticular**

**9 Adrenal tumours**

**4 Colon / rectum**

**3 Gynaecological**

**2 Pelvic**

**1 Bones**

**1 Retroperitoneum**

**1 Stomach**

**1 Liver**

## Chart 10

### Total Registrations per Region - 1 Prostate, Bladder, Kidney, Testis, Pelvis/Ureter & Penile Tumours\*

Region	2002 Total Registrations* BAUS	National figures**	2002 BAUS % National	2001 BAUS % National	% Change from 2001#
<b>England: ##</b>					
Eastern	2505	4077	61.4%	-	-
EA & Oxford	-	-	-	47.7%	-
London	2069	4252	48.7%	-	-
Northern & Yorks	3484	4679	74.5%	81.2%	-6.7%
North Thames	-	-	-	57.5%	-
North Western	2976	4991	59.6%	41.5%	+18.1%
South Eastern	4486	6960	64.5%	-	-
South Thames	-	-	-	60.5%	-
South Western	2516	4706	53.5%	67.3%	-13.8%
Trent	2345	3878	60.5%	73.2%	-12.7%
West Midlands	2368	4533	52.2%	70.0%	-17.8%
<b>Total England</b>	<b>22749</b>	<b>38076</b>	<b>59.7%</b>	<b>62.2%</b>	<b>-2.5%</b>
Scotland	3016	3611	83.5%	50.7%	+32.8%
Wales	1909	3112	61.3%	54.9%	+6.4%
Northern Ireland	319	988	32.3%	36.2%	-3.9%
<b>Total UK</b>	<b>27993</b>	<b>45787</b>	<b>61.1%</b>	<b>60.2%</b>	<b>+0.9%</b>

\*\*England : cancer statistics - registrations of cancer diagnosed in 1999, England. Series MBI no. 30 - 2003

Wales: Welsh Cancer Intelligence & Surveillance Unit - 2001

Scotland: Scottish Cancer Registry, Scottish Cancer Intelligence Group, ISD Scotland - 1999

Northern Ireland: Northern Ireland Cancer Registry - 2000 - www.qub.ac.uk/nicr

## Change to Regional Health Offices in 1999

# Change in BAUS returns for 2002 of 2001 as a % of the National figures

## Chart 11

### Total Registrations per Region - 2

Region	Prostate BAUS	National		Bladder BAUS	National		Kidney BAUS	National	
		figures*	BAUS % National		figures*	BAUS % National		figures*	BAUS % National
<b>England:</b>									
Eastern	1167	2464	63.6%	626	908	68.9%	169	433	39.0%
London	1830	2582	51.4%	493	906	54.4%	156	488	32.0%
Northern & Yorks	1619	2566	76.1%	1012	1176	86.1%	311	606	51.3%
North Western	1068	2602	67.5%	793	1456	54.5%	212	615	34.5%
South Eastern	1859	4021	70.7%	1094	1770	61.8%	325	721	45.1%
South Western	2356	2450	62.0%	661	1505	43.9%	198	468	42.3%
Trent	1377	1785	72.1%	711	1388	51.2%	217	445	48.8%
West Midlands	1836	2372	62.1%	599	1415	42.3%	189	502	37.6%
<b>Total England</b>	<b>13112</b>	<b>20842</b>	<b>65.9%</b>	<b>5989</b>	<b>10524</b>	<b>56.9%</b>	<b>1777</b>	<b>4278</b>	<b>41.5%</b>
Scotland	1495	1925	77.7%	1014	831	122.0%	271	570	47.5%
Wales	1150	1736	66.2%	504	900	56.0%	178	341	52.2%
Northern Ireland	178	542	32.8%	77	214	36.0%	39	132	29.5%
<b>Total UK</b>	<b>16549</b>	<b>25045</b>	<b>66.1%</b>	<b>7584</b>	<b>12469</b>	<b>60.8%</b>	<b>2265</b>	<b>5321</b>	<b>42.6%</b>

\*\*England : cancer statistics - registrations of cancer diagnosed in 1999, England. Series MBI no. 30 - 2003

Wales: Welsh Cancer Intelligence & Surveillance Unit - 2001

Scotland: Scottish Cancer Registry, Scottish Cancer Intelligence Group, ISD Scotland - 1999

Northern Ireland: Northern Ireland Cancer Registry - 2000 - www.qub.ac.uk/nicr

## Chart 12

### Total Registrations per Region - 3

Region	Testis BAUS	National figures*	BAUS % National	Pelvis/ Ureter BAUS	National figures*	BAUS % National	Penis BAUS	National figures*	BAUS % National
<b>England:</b>									
Eastern	75	188	39.9%	36	61	59.0%	32	23	139.1%
London	56	215	26.0%	18	29	62.1%	19	32	59.4%
Northern & Yorks	115	212	54.2%	64	80	80.0%	30	39	76.9%
North Western	140	218	64.2%	51	56	91.1%	23	44	52.3%
South Eastern	138	327	42.2%	60	71	84.5%	26	50	52.0%
South Western	78	205	38.0%	36	49	73.5%	23	29	79.3%
Trent	77	163	47.2%	27	59	45.8%	26	38	68.4%
West Midlands	74	148	50.0%	20	74	27.0%	13	22	59.1%
<b>Total England</b>	<b>753</b>	<b>1676</b>	<b>44.9%</b>	<b>312</b>	<b>479</b>	<b>65.1%</b>	<b>192</b>	<b>277</b>	<b>69.3%</b>
Scotland	153	188	81.4%	57	61	93.4%	26	36	72.2%
Wales	57	79	72.2%	7	38	18.4%	13	18	72.2%
Northern Ireland	17	68	25.0%	4	14	28.6%	4	18	22.2%
<b>Total UK</b>	<b>980</b>	<b>2011</b>	<b>48.7%</b>	<b>358</b>	<b>592</b>	<b>64.2%</b>	<b>235</b>	<b>349</b>	<b>67.3%</b>

\*\*England : cancer statistics - registrations of cancer diagnosed in 1999, England. Series MBI no. 30 - 2003  
 Wales: Welsh Cancer Intelligence & Surveillance Unit - 2001  
 Scotland: Scottish Cancer Registry, Scottish Cancer Intelligence Group, ISD Scotland - 1999  
 Northern Ireland: Northern Ireland Cancer Registry - 2000 - www.qub.ac.uk/nicr

## Chart 13

### Laterality by Organ

Organ	Total Number Recorded	Laterality recorded & % of total	Left Side *	Right Side *
Kidney	2273	2133 93.8%	1010 47.4%	1123
Testis	984	928 94.3%	455 49.0%	473
Pelvis/Ureter	382	332 86.9%	170 51.2%	162


\* Number and percentage of those where laterality was recorded

## Chart 14

- **Total number of synchronous bilateral tumours = 15**  
**10 Kidney**  
**3 Pelvis/ureter**  
**2 Testicular**
- **Total number of Tumours registered twice = 740**  
**(Tertiary referral from another centre or another consultant in the same centre). Only included once in all analyses**
- **Total number of patients where there were tumours in different organs in the same year = 178**  
**(including 2 patients with 3 separate tumours)**

## Chart 15

**Percentage Age Distribution - Prostate Tumours**  
**BAUS 2002 median: 72 Years; Range 20 -102 (n= 16,276\*)**




\* Age could be calculated when both date of birth and diagnosis date were recorded = 16,276/16,580 = 98%

\*\* National figures are for 1999 (England and Scotland ), 2000 (Northern Ireland) and 2001 (Wales)

## Chart 16

### Percentage Age Distribution - Bladder Tumours - Males BAUS 2002 median Males: 72 Years; Range 20 -101 (n= 5,556\*)




\* Sex was recorded in 7552/7611 (99%) bladder tumours (5631 males & 1921 females)

Age could be calculated when both date of birth and diagnosis date were recorded = 5556/5631 (99%) & 1878/1921 (98%)

\*\* National figures are for 1999 (England and Scotland), 2000 (Northern Ireland) and 2001 (Wales)

## Chart 17

### Percentage Age Distribution - Bladder Tumours - Females BAUS 2001 median Females: 74 Years; Range 18 -100 (n= 1,878\*)




\* Sex was recorded in 7552/7611 (99%) bladder tumours (5631 males & 1921 females)

Age could be calculated when both date of birth and diagnosis date were recorded = 5556/5631 (99%) & 1878/1921 (98%)

\*\* National figures are for 1999 (England and Scotland), 2000 (Northern Ireland) and 2001 (Wales)

## Chart 18

### Percentage Age Distribution - Kidney Tumours- Males BAUS 2001 median Males : 66 Years; Range 23 -93 (n= 1,371\*)




\* Sex was recorded in 2255/2270 (99.3%) kidney tumours (1420 males & 835 females)

Age could be calculated when both date of birth and diagnosis date were recorded = 1371/1420 (96.5%) & 800/835 (95.8%)

\*\* National figures are for 1999 (England and Scotland ), 2000 (Northern Ireland) and 2001 ( Wales)

## Chart 19

### Percentage Age Distribution - Kidney Tumours - Females BAUS 2002 median Females : 67 Years; Range 24 -95 (n= 800\*)



\* Sex was recorded in 2255/2270 (99.3%) kidney tumours (1420 males & 835 females)


Age could be calculated when both date of birth and diagnosis date were recorded = 1371/1420 (96.5%) & 800/835 (95.8%)

\*\* National figures are for 1999 (England and Scotland ), 2000 (Northern Ireland) and 2001 ( Wales)

## Chart 20

### Percentage Age Distribution - Testicular Tumours

BAUS 2002 median: 37 Years; Range 16 -89 (n= 964\*)



\* Age could be calculated when both date of birth and diagnosis date were recorded = 964/984 (98%).

\*\* National figures are for 1999 (England and Scotland), 2000 (Northern Ireland) and 2001 (Wales)


## Chart 21

### Percentage Age Distribution - Testicular Tumours

Seminoma median age : 38 years; Range 19 -84; Mean 39.7 years (n = 526\*)

Teratoma median age : 29 years; Range 16 - 80; Mean 31.7 years (n = 224\*)

Combined seminoma/teratoma median age : 34 years; Range 17 -71; Mean 34.8 years (n = 91\*)




\* Age could be calculated when both date of birth and diagnosis date were recorded = 964/984 (98%).

Histology was reported in 907 of these tumours. (923/964 = 95.7%), 82 of these were histologies other than the above groups



## Chart 22

**Percentage Age Distribution - Pelvis/Ureteric Tumours - Males**  
**BAUS 2002 median Males : 72 Years; Range 35 -100 (n= 240\*)**




\* Sex was recorded in 380/382 (99.5%) pelvis/ureteric tumours (244 males & 136 females)

Age could be calculated when both date of birth and diagnosis date were recorded = 240/244 (98.4%) & 134/136 (98.5%)

\*\* National figures are for 1999 (England and Scotland ), 2000 (Northern Ireland) and 2001 ( Wales)

## Chart 23

**Percentage Age Distribution - Pelvis/Ureteric Tumours - Females**  
**BAUS 2002 median Females : 72 Years; Range 40 -90 (n=134\*)**




\* Sex was recorded in 380/382 (99.5%) pelvis/ureteric tumours (244 males & 136 females)

Age could be calculated when both date of birth and diagnosis date were recorded = 240/244 (98.4%) & 134/136 (98.5%)

\*\* National figures are for 1999 (England and Scotland ), 2000 (Northern Ireland) and 2001 ( Wales)

## Chart 24

### Percentage Age Distribution - Penile Tumours BAUS 2002 median: 67 Years; Range 31 -98 (n= 225\*)



\* Age could be calculated when both date of birth and diagnosis date were recorded = 225/235 = 95.7%

\*\* National figures are for 1999 (England and Scotland ), 2000 (Northern Ireland) and 2001 ( Wales)

## B. Referral Source, Priority & Time between Referral, First Consultation, Diagnosis and Definitive Treatment

In this section we have included charts from the 2001 dataset to allow for comparisons.

'Priority of referral' has been recorded in 90% of GP referrals and has enabled analysis of patients referred under the two- week rule as distinct from other types of referral. Seventy-three (73%) of GP referrals, under the two-week rule, were seen within 14 days.

The overall time from referral to diagnosis is showing favourable trends but is still longer than in 1999. The time from consultation to diagnosis was notably shorter in Scotland than other parts of the UK but correspondingly the time from referral to consultation was notably longer.

In 2001 only 55% of the returns included the date of definitive treatment. In 2002 this has increased to over 64% but nonetheless interpretation must still be cautious. In some cases, the date of definitive treatment was recorded as being before the date of diagnosis! Any negative times between diagnosis and definitive treatment date were treated as 0 i.e. definitive treatment date = date of diagnosis.

The delays from referral to definitive treatment are substantial and disease progression during this time should be considered.

Under the new government cancer waiting times targets\* (implemented from April 1<sup>st</sup> 2003 for urological cancers), urgent GP referrals should be seen within 14 days, and first definitive treatment should be within 31 days for testicular cancers and 62 days for all other cancers. Non-urgent GP referrals should aim to have a maximum of 31 days between diagnosis and first definitive treatment.

\* England, Wales & N Ireland only

## Chart 25

### Source of Referral by Organ - 2002

Organ	GP		Urologist		Other		Not Recorded	
	N	%	N	%	N	%	N	%
<b>Prostate</b>	11816	71.3	1237	7.5	2320	14.0	1207	7.3
<b>Bladder</b>	5726	75.2	219	2.9	1156	15.2	510	6.7
<b>Kidney</b>	1017	44.8	167	7.4	834	36.7	252	11.1
<b>Testis</b>	748	76.0	35	3.6	142	14.4	59	6.0
<b>Pelvis/Ureter</b>	241	63.1	30	7.9	84	22.0	27	7.1
<b>Penis</b>	141	60.0	28	11.9	53	22.6	13	5.5
<b>Urethra</b>	11	44.0	3	12.0	8	32.0	3	12.0
<b>Prostatic Urethra</b>	13	68.4	3	15.8	1	5.3	2	10.5
<b>Other or Not Recorded</b>	180	73.5	8	3.3	41	16.7	16	6.5
<b>Totals</b>	19893	70.2	1730	6.1	4636	16.4	2089	7.4

## Chart 26

### Source of Referral by Organ - 2001

Organ	GP		Urologist		Other		Not Recorded	
	N	%	N	%	N	%	N	%
Prostate	11648	77.1	724	4.8	1681	1.1	0146	6.9
Bladder	5967	77.2	155	2.0	1028	13.3	580	7.5
Kidney	1108	53.3	92	4.4	753	36.4	118	5.7
Testis	736	76.4	44	4.6	124	12.9	59	6.1
Pelvis/Ureter	238	66.5	32	8.9	64	17.9	24	6.7
Penis	140	64.5	17	7.8	48	22.1	12	5.5
Urethra	23	62.2	2	5.4	7	18.9	5	13.5
Prostatic Urethra	12	63.2	2	10.5	4	21.1	1	5.3
Other or Not Recorded	151	59.9	6	2.4	45	17.9	50	19.8
Totals	20023	74.9	1074	4.0	3754	14.0	1895	7.1

## Chart 27

### “Other” Sources of Referral by Organ included:

	Prostate	Bladder	Kidney	Testis	Pelvis/Ureter	Penis	Urethra	Prostatic Urethra
Consultant Physicians	496	241	302	11	16	15	1	-
Consultant Surgeons	366	163	196	27	11	9	1	-
A & E	325	297	99	32	16	1	-	-
Gynaecology	-	110	20	-	4	-	2	-
Care of Elderly	92	34	16	-	1	-	-	-
Haematology	23	15	23	1	2	-	-	-
Oncologists	53	11	30	12	1	2	1	-
Discovered during Urological Follow-up	436	122	30	3	19	4	1	-
Radiology	7	4	8	34	1	-	-	-
Incidental Finding	101	17	17	1	2	1	-	-
Other	283	86	56	10	8	13	1	1

## Chart 28

### Source of Referral by Region - 2002 Region could be identified in 28303/28351 tumours (99.8%)\*

Region	GP		Urologist		Other		Not Recorded	
	N	%	N	%	N	%	N	%
<b>England:</b>								
Eastern	1877	74.5	124	4.9	366	14.5	154	6.1
London	1080	51.9	95	4.6	407	19.5	500	24.0
Northern & Yorks	2581	71.8	204	5.7	572	15.9	237	6.6
North Western	1867	62.2	560	18.6	520	17.3	57	1.9
South Eastern	3181	70.6	280	6.2	621	13.8	425	9.4
South West	1925	75.9	102	4.0	387	15.3	122	4.8
Trent	1747	73.9	59	2.5	457	19.3	102	4.3
West Midlands	1721	72.1	165	6.9	427	17.9	74	3.1
<b>Total England</b>	<b>15979</b>	<b>69.5</b>	<b>1589</b>	<b>6.9</b>	<b>3757</b>	<b>16.3</b>	<b>1671</b>	<b>7.3</b>
<b>Scotland</b>	<b>2273</b>	<b>75.4</b>	<b>58</b>	<b>1.9</b>	<b>484</b>	<b>16.0</b>	<b>201</b>	<b>6.7</b>
<b>Wales</b>	<b>1360</b>	<b>70.1</b>	<b>49</b>	<b>2.5</b>	<b>327</b>	<b>16.9</b>	<b>204</b>	<b>10.5</b>
<b>Northern Ireland</b>	<b>237</b>	<b>72.0</b>	<b>30</b>	<b>9.1</b>	<b>57</b>	<b>17.3</b>	<b>5</b>	<b>1.5</b>
<b>Total UK</b>	<b>19849</b>	<b>70.2</b>	<b>1726</b>	<b>6.1</b>	<b>4625</b>	<b>16.4</b>	<b>2081</b>	<b>7.4</b>

\* 22 registrations came from Eire and are not included above

## Chart 29

### Priority of GP Referrals by Organ 2002

Priority	Prostate	Bladder	Kidney	Testis	Pelvis/ Ureter	Penis	Totals
N / %	(11820)	(5729)	(272)	(1018)	(243)	(147)	(19710)
<b>Under 2 week rule</b>	3397	1792	348	353	72	51	6013
	28.7%	31.3%	34.2%	46.9%	29.6%	34.7%	30.5%
<b>Under 2 week rule downgraded</b>	90	31	3	5	0	1	130
	0.8%	0.5%	0.3%	0.7%		0.7%	0.7%
<b>Emergency</b>	452	322	103	20	18	6	921
	3.8%	5.6%	10.1%	2.7%	7.4%	4.1%	4.7%
<b>Urgent</b>	3754	1957	366	234	92	48	6451
	31.8%	34.2%	36.0%	31.1%	37.9%	32.7%	32.7%
<b>Routine</b>	3006	1103	124	55	39	27	4354
	25.4%	19.3%	12.2%	7.3%	16.0%	18.4%	22.1%
<b>Discovered during urological follow-up</b>	45	8	2	0	1	0	56
	0.4%	0.1%	0.2%		0.4%		0.3%
<b>Unknown / Not Recorded</b>	1072	513	71	81	19	8	1764
	9.1%	9.0%	7.0%	10.8%	7.8%	5.4%	8.9%


## Chart 30

### Priority of GP Referrals by Organ - 2001

Organ	With suspicion of cancer		Routine		Discovered During Follow-up		Other / Not Recorded	
	N	%	N	%	N	%	N	%
Prostate (11648)	6012	51.6	2674	23.0	597	5.1	2365	20.3
Bladder (5967)	3358	56.3	1235	20.7	137	2.3	1237	20.7
Kidney (1108)	662	59.7	174	15.7	45	4.1	227	20.5
Testis (736)	519	70.5	55	7.5	7	1.0	155	21.1
Pelvis/Ureter (238)	133	55.9	40	16.8	18	7.6	47	19.7
Penis (140)	74	52.9	28	20.0	4	2.9	34	24.3

## Chart 31

### Median Time to First Consultation and Diagnosis in Days by Referral Source in Days Excluding tumours diagnosed before Referral\* - 2002



\* Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date ( N = 22,634/28,351 = 79.8% tumours)  
 Referral Source was recorded in 22,349/22,634 cases:  
 GP - 18060/19893 = 90.8%; Urologist 745/1730 = 43.1%; Other 3544/4639 = 76.4%).  
 Referral priority was recorded in 93.5% (16888/18060) GP referrals

## Chart 32

### Times to First Consultation and Diagnosis in Days when referred by GP (18,060 tumours) Excluding those diagnosed before Referral - 2002

Days	Time to first Consultation		Time from first consultation to Diagnosis	
	N	%	N	%
<b>0 *</b>	1236	6.8	2279	12.6
<b>1 – 14</b>	6434	35.6	3368	18.6
<b>15 – 28</b>	3807	21.1	3035	16.8
<b>29 - 60</b>	4057	22.5	4367	24.2
<b>More than 60 days</b>	2526	14.0	5011	27.7

\* = the number seen either on the day  
of referral or diagnosed at first consultation

## Chart 33

### Times to First Consultation and Diagnosis in Days when referred by GP under the 2 week rule (5,740 tumours) Excluding those diagnosed before Referral - 2002

Days	Time to first Consultation		Time from first consultation to Diagnosis	
	N	%	N	%
<b>0 *</b>	132	2.3	780	13.6
<b>1 – 14</b>	4058	70.7	1342	23.4
<b>15 – 28</b>	955	16.6	1103	19.2
<b>29 - 60</b>	471	8.2	1465	25.5
<b>More than 60 days</b>	124	2.2	1050	18.3

\* = the number seen either on the day  
of referral or diagnosed at first consultation

### Chart 34

**Times to First Consultation and Diagnosis in Days  
when referred by a Urologist (745 tumours)  
Excluding those diagnosed before Referral - 2002**

Days	Time to first Consultation		Time from first consultation to Diagnosis	
	N	%	N	%
<b>0 *</b>	<b>190</b>	<b>25.5</b>	<b>178</b>	<b>23.9</b>
<b>1 – 14</b>	<b>159</b>	<b>21.3</b>	<b>168</b>	<b>22.6</b>
<b>15 – 28</b>	<b>136</b>	<b>18.3</b>	<b>95</b>	<b>12.7</b>
<b>29 - 60</b>	<b>154</b>	<b>20.7</b>	<b>168</b>	<b>22.6</b>
<b>More than 60 days</b>	<b>106</b>	<b>14.2</b>	<b>136</b>	<b>18.2</b>

\* = the number seen either on the day of referral or diagnosed at first consultation

### Chart 35

**Times to First Consultation and Diagnosis in Days  
when referred by “Other” source (3,544 tumours)  
Excluding those diagnosed before Referral - 2002**


Days	Time to first Consultation		Time from first consultation to Diagnosis	
	N	%	N	%
<b>0 *</b>	<b>1280</b>	<b>36.1</b>	<b>499</b>	<b>14.1</b>
<b>1 – 14</b>	<b>982</b>	<b>27.7</b>	<b>935</b>	<b>26.4</b>
<b>15 – 28</b>	<b>444</b>	<b>12.5</b>	<b>490</b>	<b>13.8</b>
<b>29 - 60</b>	<b>495</b>	<b>14.0</b>	<b>639</b>	<b>18.0</b>
<b>More than 60 days</b>	<b>343</b>	<b>9.7</b>	<b>981</b>	<b>27.7</b>

\* = the number seen either on the day of referral or diagnosed at first consultation



## Chart 36

**Median Time to First Consultation and Diagnosis in Days by Region for tumours referred by GP - 2002  
Excluding tumours diagnosed before Referral\***



\* Times were calculated when region, dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date N = 18,035/19,849 = 90.9% of GP referrals


## Chart 37

**Times to First Consultation and Diagnosis in Days by Region for tumours referred by GP - 2002  
Excluding tumours diagnosed before Referral**

Region	Time to Consultation			Time to Diagnosis		
	Median	Mean	Range (0-95%) in days	Median	Mean	Range (0-95%) In days
Eastern (1743 tumours)	19	50.9	0 - 101	23	68.2	0 - 237
London (980 tumours)	18	54.1	0 - 121	34	84.2	0 - 307
Northern & Yorks (2348 tumours)	15	31.9	0 - 85	32	77.4	0 - 258
North Western (1753 tumours)	18	33.4	0 - 116	36	103.1	0 - 422
South East (2772 tumours)	7	47.5	0 - 104	31	72.4	0 - 294
South Western (1775 tumours)	17	50.6	0 - 96	29	21.2	0 - 273
Trent (1619 tumours)	14	46.3	0 - 101	31	77.8	0 - 309
West Midlands (1563 tumours)	17	29.1	0 - 84	32	76.1	0 - 254
Total England (14568 tumours)	17	42.4	0 - 100	31	77.7	0 - 300
Scotland (2085 tumours)	34	64.5	0 - 138	17	76.2	0 - 331
Wales (1158 tumours)	23	39.9	0 - 129	45	104.0	0 - 398
Northern Ireland (224 tumours)	20	32.6	0 - 90	23	93.5	0 - 484

## Chart 38


**Median Time to First Consultation and Diagnosis in Days by Organ  
Excluding tumours diagnosed before Referral\*  
2002 dataset**



\* Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date (N = 22,634/28,351 = 79.8% tumours - Bladder = 6466/7612 = 84.9%; Kidney = 1573/2273 = 69.2%; Testis = 805/984 = 81.8%; Pelvis/Ureter = 291/382 = 76.2%; Penis = 194/235 = 82.6%. Prostate tumours were only included if they were >T1b = 11802/12737 = 92.6%


## Chart 39

**Median Time to First Consultation and Diagnosis in Days by Organ  
Excluding tumours diagnosed before Referral\*  
2001 dataset**



\* Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date (N = 21,632/26,746 = 80.9% tumours - Bladder = 6424/7730 = 83.1%; Kidney = 1542/2071 = 74.5%; Testis = 785/963 = 81.5%; Pelvis/Ureter = 295/358 = 82.4%; Penis = 167/217 = 77.0%. Prostate tumours were only included if they > T1b = 10937/11966 = 91.4%

## Chart 40



\* Times were calculated when dates of referral, consultation and diagnosis were known and diagnosis date was not before referral date ((N = 22,634/28,351 = 79.8% tumours - Prostate = 3268/3487 = 93.7%; Bladder = 1708/1946 = 87.8%; Kidney = 303/347 = 87.3%; Testis = 326/379 = 86.0%; Pelvis/Ureter = 67/75 = 89.3%; Penis = 48/57 = 84.2%. Prostate tumours were only included if they > T1b = 2607/2722 = 95.8%

## Chart 41


**Times to First Consultation and Diagnosis in Days - All Referrals  
Excluding Patients Diagnosed before Referral**

Year	Time between Referral and First Consultation in Days			Time between First Consultation and Diagnosis in Days		
	Median	Mean	Range (0 - 95%)	Median	Mean	Range (0 - 95%)
2002 (22,634)	17	43.9	0 - 106	29	85.6	0 - 332
2001 (21,632)	19	34.0	0 - 107	30	87.2	0 - 327
2000 (18,722)	22	35.1	0 - 109	29	77.0	0 - 272
1999 (15,912)	-	-	-	53*	84.7*	0 - 282*

\* In 1999 only referral date and diagnosis date were recorded therefore these figures represent total time to diagnosis

## Chart 42

### Median Total Times to Diagnosis in Days - All Referrals Excluding Patients Diagnosed before Referral



## Chart 43

### Times to Definitive Treatment in Days by Organ - 2002 Excluding tumours diagnosed or treated before referral

Organ	Time between Referral and Definitive Treatment in days			Time between Diagnosis and Definitive Treatment in days		
	Median	Mean	Range (0 - 95%)	Median	Mean	Range (0 - 95%)
Prostate (7175)	105	177.1	0 - 569	27	43.5	0 - 135
Bladder (3631)	68	112.4	0 - 288	0	20.1	0 - 85
Kidney (933)	58	141.8	0 - 278	0	14.3	0 - 77
Testis (473)	16	65.6	0 - 154	0	4.8	0 - 28
Pelvis/Ureter (186)	96	128.0	4 - 337	16	16.5	0 - 105
Penis (118)	61	81.6	2 - 263	7	21.9	0 - 83

Definitive treatment date was recorded in 64.4% tumours (18273/28351)

## Chart 44

### Times to Definitive Treatment in Days by Organ - 2001

Organ	Time between Referral and Definitive Treatment in days			Time between Diagnosis and Definitive Treatment in days		
	Median	Mean	Range (0 – 95%)	Median	Mean	Range (0 – 95%)
Prostate (5764)	93	178.4	0 – 569	20	43.5	0 – 135
Bladder (4384)	63	111.3	0 – 287	0	22.3	0 – 79
Kidney (1118)	55	90.8	0 – 279	0	16.3	0 – 57
Testis (578)	15	37.4	0 – 122	0	7.29	0 – 28
Pelvis/Ureter (226)	105	192.0	0 – 578	0	25.8	0 – 90
Penis (106)	50	95.1	4 – 353	0	25.1	0 – 88

Definitive treatment date was recorded in 55.3% tumours (14787/26746)

## Chart 45

### Times to Definitive Treatment in Days by Organ - 2002 When referred by GP under the two week rule excluding tumours diagnosed or treated before referral

Organ	Time between Referral and Definitive Treatment in days			Time between Diagnosis and Definitive Treatment in days		
	Median	Mean	Range (0 – 95%)	Median	Mean	Range (0 – 95%)
Prostate (1789)	65	92.5	0 – 248	22	31.9	0 – 141
Bladder (917)	54	67.1	0 – 190	0	8.5	0 – 83
Kidney (175)	65	178.2	6 – 158	0	8.2	0 – 78
Testis (191)	15	67.8	0 – 70	0	32.1	0 – 28
Pelvis/Ureter (38)	81	120.7	15 – 255	7	10.9	0 – 79
Penis (27)	55	62.5	6 – 142	21	32.1	0 – 82

Definitive treatment date was recorded in 66.7% tumours referred by GP under the 2 week rule (4174/6254)

## Chart 46

**Times to Definitive Treatment in Days by Organ - 2001  
When referred by GP with suspicion of cancer**

Organ	Time between Referral and Definitive Treatment in days			Time between Diagnosis and Definitive Treatment in days		
	Median	Mean	Range (0 – 95%)	Median	Mean	Range (0 – 95%)
Prostate (2809)	75	122.9	0 – 302	20	41.5	0 – 126
Bladder (2151)	58	83.7	0 – 186	0	23.1	0 – 80
Kidney (441)	54	73.2	0 – 184	0	16.8	0 – 58
Testis (367)	15	29.5	0 – 91	0	8.5	0 – 28
Pelvis/Ureter (90)	95	115.1	5 – 399	0	22.7	0 – 77
Penis (45)	45	67.5	4 – 177	0	31.6	0 – 126

Definitive treatment date was recorded in 66.9% tumours referred by GP under suspicion of cancer(6634/9922))

## Chart 47

**Times to Definitive Treatment in Days - Prostate Cancer by Stage - 2002  
When referred by GP under the two week rule  
excluding tumours diagnosed or treated before referral**

Stage	N	Time between Referral and Definitive Treatment in days			Time between Diagnosis and Definitive Treatment in days		
		Median	Mean	Range (0 – 95%)	Median	Mean	Range (0 – 95%)
Stage I (T1a N0 M0 Well Differentiated)	7	102	139.6	59 – 172	44	84	0 – 84
Stage II (T1a N0 M0 Mod or Poor differentiation T1b, 1c, 1, 2, N0 M0 Any differentiation)	<i>T1 - 76</i> <i>T1a - 7</i> <i>T1b - 7</i> <i>T1c - 220</i> <i>T2 - 426</i>	101 54 78 98 79	134.5 63.8 103.1 124.3 98.6	4 – 353 25 – 99 49 – 150 13 – 301 0 – 238	35 13 33 37 28	57.3 10.3 28.0 55.2 42.6	0 – 177 0 – 28 0 – 79 0 – 147 0 – 151
Stage III (T3 N0 M0 Any differentiation)	449	53	109.9	0 – 228	19	24.6	0 – 123
Stage IV (T4 N0 M0 Any differentiation Any T N1 M0 Any differentiation Any T Any N M1 Any differentiation)	369	35	2.3	0 – 166	12	9.3	0 – 74

## Chart 48

**Times to Definitive Treatment in Days - Prostate Cancer by Stage - 2001  
When referred by GP with suspicion of cancer**

Stage	N	Time between Referral and Definitive Treatment in days			Time between Diagnosis and Definitive Treatment in days		
		Median	Mean	Range (0 - 95%)	Median	Mean	Range (0 - 95%)
Stage I (T1a N0 M0 Well Differentiated)	10	78	48.7	0 - 120	0	10.7	0 - 15
Stage II (T1a N0 M0 Mod or Poor differentiation T1b, 1c, 1, 2, N0 M0 Any differentiation)	<i>T1 - 89</i> <i>T1a - 21</i> <i>T1b - 26</i> <i>T1c - 389</i> <i>T2 - 764</i>	119 108 69 125 102	209.6 228.8 266.9 163.7 151.3	0 - 517 0 - 547 0 - 560 0 - 354 0 - 390	43 9 4 43 34	58.0 52.2 51.4 60.8 52.0	0 - 135 0 - 132 0 - 118 0 - 163 0 - 142
Stage III (T3 N0 M0 Any differentiation)	855	64	99.7	0 - 226	17	35.2	0 - 105
Stage IV (T4 N0 M0 Any differentiation Any T N1 M0 Any differentiation Any T Any N M1 Any differentiation)	675	37	74.5	0 - 177	4	22.2	0 - 79

## Chart 49

**Times to First Consultation, Diagnosis and Definitive Treatment in Days  
by Prostate (11802 tumours)- 2002 dataset  
Excluding tumours diagnosed before Referral and those with T1a or T1b**

Days	Time to first Consultation		Time from first consultation to Diagnosis		Time from Diagnosis to Definitive Treatment	
	N	%	N	%	N	%
0 *	1102	9.3	1536	13.0	1809	5.3
1 - 14	3922	33.2	2274	19.3	1165	9.9
15 - 28	2413	20.4	1821	15.4	1147	9.7
29 - 60	2666	22.6	605	22.1	1298	11.0
More than 60 days	1699	14.4	3566	30.2	2009	17.0
Not Recorded	-		-		4374	37.1

\* = the number seen either on the day of referral or diagnosed and/or treated at first consultation

## Chart 50

### Times to First Consultation, Diagnosis and Definitive Treatment in Days by Prostate (10937 tumours)- 2001 dataset Excluding tumours diagnosed before Referral and those with T1a or T1b

Days	Time to first Consultation	Time from first consultation to Diagnosis	Time from Diagnosis to Definitive Treatment
0 *	905 – 8.3%	1301 – 11.9%	1473 - 13.5%
1 – 14	3253 – 29.7%	2217 – 20.3%	1705 – 15.6%
15 – 28	2478 – 22.6%	1518 – 13.9%	881 – 8.1%
29 - 60	2522 – 23.1%	2601 – 23.8%	1062 – 9.7%
More than 60 days	1779 – 16.3%	3300 – 30.2%	1422 – 13.0%
Not Recorded	-	-	4394 – 40.2%

\* = the number seen either on the day of referral or diagnosed and/or treated at first consultation

## Chart 51

### Times to First Consultation, Diagnosis and Definitive Treatment in Days by Bladder (6466 tumours)- 2002 dataset Excluding tumours diagnosed before Referral

Days	Time to first Consultation		Time from first consultation to Diagnosis		Time from Diagnosis to Definitive Treatment	
	N	%	N	%	N	%
0 *	884	13.7	962	14.9	3224	49.9
1 – 14	2070	32.0	1227	19.0	365	5.6
15 – 28	1342	20.8	1186	8.3	439	6.8
29 - 60	1376	21.3	1698	26.3	535	8.3
More than 60 days	794	2.3	1393	21.5	387	6.0
Not Recorded	-		-		1516	23.4

\* = the number seen either on the day of referral or diagnosed and/or treated at first consultation



## Chart 52

### Times to First Consultation, Diagnosis and Definitive Treatment in Days by Bladder (6424 tumours) - 2001 dataset Excluding those diagnosed before Referral

Days	Time to first Consultation	Time from first consultation to Diagnosis	Time from Diagnosis to Definitive Treatment
0 *	801 – 12.5%	779 – 12.1%	2945 - 45.8%
1 – 14	1877 – 29.2%	1284 – 20.0%	1674 – 26.1%
15 – 28	1492 – 23.2%	1171 – 18.2%	341 – 5.3%
29 - 60	1480 – 23.0%	1705 – 26.5%	496 – 7.7%
More than 60 days	774 – 12.0%	1485 – 23.1%	346 – 5.4%
Not Recorded	-	-	622 – 9.7%

\* = the number seen either on the day of referral or diagnosed and/or treated at first consultation

## Chart 53

### Times to First Consultation, Diagnosis and Definitive Treatment in Days by Kidney (1573 tumours)- 2002 dataset Excluding tumours diagnosed before Referral

Days	Time to first Consultation		Time from first consultation to Diagnosis		Time from Diagnosis to Definitive Treatment	
	N	%	N	%	N	%
0 *	351	22.3	177	11.3	933	59.3
1 – 14	635	40.4	281	17.9	83	5.3
15 – 28	246	15.6	275	17.5	86	5.5
29 - 60	228	14.5	434	27.6	108	6.9
More than 60 days	113	7.2	406	25.8	86	5.5
Not Recorded	-		-		570	36.2

\* = the number seen either on the day of referral or diagnosed and/or treated at first consultation

## Chart 54

### Times to First Consultation, Diagnosis and Definitive Treatment in Days by Kidney (1542 tumours) - 2001 dataset Excluding those diagnosed before Referral

Days	Time to first Consultation	Time from first consultation to Diagnosis	Time from Diagnosis to Definitive Treatment
0 *	279 – 18.1%	173 – 11.2%	818 – 53.1%
1 – 14	668 – 43.3%	297 – 19.3%	451 – 29.2%
15 – 28	264 – 17.1%	294 – 19.1%	84 – 5.5%
29 - 60	228 – 14.8%	378 – 24.5%	96 – 6.2%
More than 60 days	103 – 6.7%	400 – 25.9%	51 – 3.3%
Not Recorded	-	-	42 – 2.7%

\* = the number seen either on the day of referral or diagnosed and/or treated at first consultation

## Chart 55

### Times to First Consultation, Diagnosis and Definitive Treatment in Days by Testis (805 tumours)- 2002 dataset Excluding tumours diagnosed before Referral

Days	Time to first Consultation		Time from first consultation to Diagnosis		Time from Diagnosis to Definitive Treatment	
	N	%	N	%	N	%
0 *	147	18.3	102	12.7	520	64.6
1 – 14	468	58.1	461	57.3	103	12.8
15 – 28	79	9.8	133	16.5	24	3.0
29 - 60	63	7.8	68	8.4	19	2.4
More than 60 days	48	6.0	41	5.1	5	0.6
Not Recorded	-		-		134	16.6

\* = the number seen either on the day of referral or diagnosed and/or treated at first consultation

## Chart 56

### Times to First Consultation, Diagnosis and Definitive Treatment in Days by Testis (785 tumours) - 2001 dataset Excluding those diagnosed before Referral

Days	Time to first Consultation	Time from first consultation to Diagnosis	Time from Diagnosis to Definitive Treatment
0 *	128 – 16.3%	90 – 11.5%	445 – 56.7%
1 – 14	478 – 61.0%	473 – 60.3%	285 – 36.3%
15 – 28	95 – 12.1%	116 – 14.8%	21 – 2.7%
29 - 60	55 – 7.0%	62 – 7.9%	20 – 2.5%
More than 60 days	29 – 3.7%	44 – 5.6%	8 – 1.0%
Not Recorded	-	-	6 – 0.8%

\* = the number seen either on the day of referral or diagnosed and/or treated at first consultation

## C. Histology

Histological confirmation was available in 89% of all tumours. This figure may reflect the fact that many participants use their histology departments to prompt registration of new patients. Every effort should be made to record data on patients seen in clinics and on the wards, where there is no histological diagnosis.

### Chart 57

#### Histological Confirmation of Diagnosis by Organ

Organ	Confirmation Obtained		Confirmation Not Obtained		Not Recorded	
	N	%	N	%	N	%
Prostate (16580)	15451	93.2	695	4.2	434	2.6
Bladder (7611)	6575	86.4	279	3.7	757	9.9
Kidney (2270)	1590	70.0	407	17.9	273	12.0
Testis (984)	842	85.6	27	2.7	115	11.7
Pelvis/Ureter (382)	317	83.0	24	6.3	41	10.7
Penis (235)	215	91.5	7	3.0	13	5.5
Urethra (25)	22	88.0	2	8.0	1	4.0
Prostatic Urethra (19)	19	100	-	-	-	-
Other or Not Recorded (245)	85	34.7	20	8.2	140	57.1
Totals (28351)	25116	88.6	1461	5.2	1774	6.3

## Chart 58

### Known Histology by Organ

	Prostate	Bladder	Kidney	Testis	Pelvis/ Ureter	Penis	Urethra	Prostatic Urethra
Adenocarcinoma	15212 98.6%	102 1.4%	1569* 83.9%	5 0.5	10 3.0%	1 0.5%	2 8.0%	5 26.3%
TCC	37 0.2%	6822 94.8%	143 7.7%	2 0.2%	315 94.6%	-	14 56.0%	11 57.9%
SCC	31 0.2%	129 1.8	12 0.6%	6 0.6%	1 0.3%	205 93.6%	5 20.0%	-
Mixed TCC / SCC	-	20 0.3%	3 0.2%	3 0.3%	2 0.6%	1 0.5%	-	1 5.3%
Seminoma	-	-	2 0.1%	529 56.9%	1 0.3%	-	-	-
Teratoma	-	-	-	228 24.5%	-	-	-	-
Mixed Seminoma / Teratoma	-	-	-	90 9.7%	-	-	-	-
High Grade PIN	101 0.7	-	-	-	-	-	-	-
Other	47 0.3%	124 1.7%	140 7.5%	67 7.2%	4 1.2%	12 5.5%	4 16.0%	2 10.6%

\*N.B. Includes 1440 renal cell carcinomas

## Chart 59

### “Other” Histologies reported included:

	Prostate	Bladder	Kidney	Testis	Penis
Carcinoma in situ	-	36	2	1	7
Oncocytoma	-	5	23	-	-
Sarcoma/Liposarcoma /Leiomyosarcoma	-	16	9	3	-
Haematological cancers	1	5	2	37	-
Leydig cell	-	-	-	13	-
Adenocarcinoma & TCC	-	1	-	-	-
Sertoli	-	-	-	2	-
Melanoma	-	1	-	-	-
Small cell ca/papillary renal cell / spindle cell	2	10	80	-	-
Undifferentiated / anaplastic carcinoma	1	8	3	-	1

## Chart 60

### Basis of Diagnosis when Histological Confirmation Not Obtained (1461 tumours - 5.2% of total)

Organ	Radiology	Cytology	Tumour Marker	Clinical	Other
Prostate (695 tumours)	120	21	440	451	35
Bladder (279 tumours)	76	35	2	114	96
Kidney (407 tumours)	376	6	-	66	7
Pelvis/Ureter (24 tumours)	17	4	-	5	4
Testis (27 tumours)	20	-	2	9	-
Penis (7 tumours)	5	-	-	2	-
Urethra (2 tumours)	-	-	-	1	1

N.B. More than one method might be used for each tumour

## Chart 61

### Known Differentiation by Organ Percentage & Total of Known Differentiation

Organ (Number Known)	Well		Moderate		Poor		% of Total Tumours Reported
	N	%	N	%	N	%	
Prostate (13270)	1415	10.7	8417	63.4	3438	25.9	80.0
Bladder (6333)	1593	25.2	2469	39.0	2271	35.9	83.2
Pelvis/Ureter (327)	56	17.1	162	49.5	109	33.3	85.6
Penis (164)	49	29.9	78	47.6	37	22.6	69.8
Urethra (19)	3	15.8	6	31.6	10	52.6	76.0
Prostatic Urethra (12)	3	25.0	1	8.3	8	66.7	63.2

N.B. Testis and Kidney not included - RCPATH minimum data set does not ask for this data which would be irrelevant to the vast majority of testicular tumours, which are mostly germ cell tumours. Kidney tumours are generally given a nuclear grade rather than a differentiation score.

## D. Staging

Participants were asked to return both clinical and, where appropriate, pathological\* TNM categories using the 1997 version of the TNM classification for Urological tumours which were included in the data dictionary sent to all participants.

In order to make interpretation of the resultant information easier each patient was staged, wherever possible, using the classifications as shown in the following charts. If the pathological TNM categories were given and appropriate then these were used for the staging, failing this the clinical TNM categories were used.

\*The pathological assessment of the primary tumour (pT) entails a “resection of the primary tumour or biopsy adequate to evaluate the highest pT category”

Less than 50% of the returns had either the full pathological TNM or clinical TNM categories and an estimate had to be made from what information was provided. (Many forms did not include any N and M categories or these were recorded as “X” – Cannot be assessed.)

The data on the following charts should therefore be regarded with caution.

The number of prostate cancers with metastases at presentation has shown a small decline since 1998. The number of T1c prostate cancers (impalpable tumours diagnosed by biopsy) has increased from 8.6% in 1998 to 18.3% in 2002.

## Chart 62

### Staging of Kidney Tumours A total of 2270 Kidney Tumours were reported Staging could be estimated in 1943 (85.6%)

Known Staging	Total Known	
	N	%
Stage I (T1 N0 M0)	703	36.2
Stage II (T2 N0 M0)	415	21.4
Stage III (T1, T2, T3 N0,N1 M0)	468	24.1
Stage IV (T4 N0,N1 M0 Any T N2 M0 Any T any N M1)	357 including 256 with metastases	18.4 13.2

N.B. A pathological staging for Kidney tumours was only included for those where radical or organ conserving surgery was performed (n =1576)

## Chart 63

### Staging of Pelvis / Ureteric Tumours

A total of 382 Tumours were reported

Staging could be estimated in 322 (84.3%)

Known Staging	Total Known	
	N	%
Stage 0a (Ta N0 M0)	82	25.5
Stage 0is (Tis N0 M0)	4	1.2
Stage I (T1 N0 M0)	85	26.4
Stage II (T2 N0 M0)	49	15.2
Stage III (T3 N0 M0)	51	15.8
Stage IV (T4 N0 M0)	51	15.8
Any T N1, N2, N3 M0 Any T any N M1)	including 13 with metastases	4.0

N.B. A pathological staging for Pelvis / Ureteric tumours was only included for those where radical or organ conserving surgery was performed (n =274)

## Chart 64

### Staging of Bladder Tumours

A total of 7611 Bladder Tumours were reported

Staging could be estimated in 6576 (86.4%)

Known Staging	Total Known	
	N	%
Stage 0a (Ta N0 M0)	3103	47.2
Stage 0is (Tis N0 M0)	111	1.7
Stage I (T1 N0 M0)	1751	26.6
Stage II (T2a, 2b N0 M0)	833	12.7
Stage III (T3a, 3b, 4a N0 M0)	490	7.5
Stage IV (T4b N0 M0)	288	4.4
Any T N1, N2, N3 M0 Any T any N M1)	including 107 with metastases	1.6

N.B. A pathological staging for Stage II, III or IV Bladder tumours was only included for tumours where radical surgery was performed (n =491)



## Chart 65

### Staging of Prostate Tumours

A total of 16580 Prostate Tumours were reported  
Staging could be estimated in 12645 (76.3%)


Known Staging	Total Known	
	N	%
Stage I (T1a N0 M0 Well Differentiated)	131	1.0
Stage II (T1a N0 M0 Mod or Poor differentiation T1b, 1c, 1, 2, N0 M0 Any differentiation)	t1 - 776 t1a - 258 t1b - 281 t1c - 2316 t2 - 3896	6.1 2.0 2.2 18.3 30.8
Stage III (T3 N0 M0 Any differentiation)	3025	23.9
Stage IV (T4 N0 M0 Any differentiation Any T N1 M0 Any differentiation Any T Any N M1 Any differentiation)	1962  including 1262 with metastases	15.5  10.0

N.B. A pathological staging for Prostate tumours was only included for those where radical surgery was performed (n=1761)

## Chart 66

### Staging of Prostate Tumours

Comparison of clinical & pathological staging




N.B. A pathological staging for Prostate tumours was only included for those where radical surgery was performed (n =1761).  
Staging could be compared in 56.4% of these (994/1761).

## Chart 67

### Staging of Prostate Tumours by Age Group

Total in Stage I where age was known = 129  
 Total in Stage II where age was known = 7533  
 Total in Stage III where age was known = 2971  
 Total in Stage IV where age was known = 1940



\* Age could be calculated when both date of birth and diagnosis date were recorded

## Chart 68

### Prostate Cancers reported 1998 - 2002

	1998 (6 months only)	1999	2000	2001	2002
Total number reported	2909	9781	12892	15099	16580
Median age at diagnosis	74	73	73	73	72
Number having T1c	250 – 8.6%	1366 – 14.0%	1636 – 12.7%	2107- 17.4%	2316 – 18.3%
Number having Metastases (M +ve)	43 – 14.9%	1214 – 12.4%	1267/10329* 12.6%	1441 / 12100* 11.9%	1262 / 12645* 10.0%

\* Number where staging could be estimated

## Chart 69

### Staging of Prostate Tumours by PSA

Numbers falling in each category\*

PSA was recorded in 87.4% tumours (14494/16580)

Gleason scores were recorded in 87.3% tumours (14468/16580)

Known Clinical Staging	Total Patients	PSA 0-5		PSA 6-10		PSA 11-20		PSA 21-50		PSA > 50	
		N	%	N	%	N	%	N	%	N	%
Stage I (T1a N0 M0 Well Differentiated)	91	47	51.6%	22	24.4%	19	20.9%	3	3.3%	0	0%
Stage II (T1a N0 M0 Mod or Poor differentiation T1b, 1c, 1, 2, N0 M0 Any differentiation)	6728	767	11.4%	2251	33.5%	2014	29.9%	1144	17.0%	552	8.2%
Stage III (T3 N0 M0 Any differentiation)	2347	78	3.3%	273	11.6%	491	20.9%	737	31.4%	768	32.7%
Stage IV (T4 N0 M0 Any differentiation Any T N1 M0 Any differentiation Any T Any N M1 Any differentiation)	1491	30	2.0%	69	4.6%	142	9.5%	276	18.5%	974	65.3%
Totals	10657 *	922	8.7%	2615	24.5%	2666	25.0%	2160	20.3%	2294	21.5%

N.B. Excluding pathologies other than Adenocarcinoma.

\* Tumours where staging could be estimated, PSA was recorded and Histology = adenocarcinoma

## Chart 70

### Gleason Sum Scores by Age Group - Prostate Tumours

Number falling into each category

Gleason scores were recorded in 87.3% (14468/16580) tumours


Age was recorded in 98.2% (14206/14468) of these

Age Group	Total Patients	Gleason sum 2 – 4		Gleason sum 5 – 6		Gleason sum 7		Gleason sum 8 – 10	
		N	%	N	%	N	%	N	%
< 60	1456	113	7.8	775	53.2	358	24.6	210	14.4
60 – 64	1691	116	6.9	826	48.8	495	29.3	254	15.0
65 – 69	2832	218	7.7	1283	45.3	768	27.1	563	19.9
70 – 74	2875	184	6.4	1124	39.1	918	31.9	649	22.6
75 – 79	2721	144	5.3	983	36.1	868	31.9	726	26.7
80 – 84	1780	103	5.8	552	31.0	547	30.7	578	32.5
85 – 89	662	26	3.9	179	27.0	204	30.8	253	38.2
>=90	189	4	2.1	45	23.8	59	31.2	81	42.9
Totals	14206	908	6.4	5767	40.6	4217	29.7	3314	23.3

**Chart 71**

**Gleason Sum Score Related to Age**

Gleason scores were recorded in 87.3% (14468/16580) tumours  
Age was recorded in 98.2% (14206/14468) of these



**Chart 72**

**Staging of Testicular Tumours**

A total of 984 Testicular Tumours were reported  
Staging could be estimated in 764 (77.6%)

Known Staging Total numbers where staging & histology known:	Seminoma 428		Teratoma 191		Combined Seminoma/ Teratoma 78		Other Histology 67	
	N	%	N	%	N	%	N	%
Stage 0 (Tis N0 M0 S0,SX)	3	0.7	1	0.5	1	1.3	1	1.5
Stage I (T1,2,3,4 N0 M0 SX)	170	39.7	80	41.9	28	35.9	29	43.3
Stage IA (T1, N0 M0 S0)	119	27.8	17	8.9	8	10.3	11	16.4
Stage IB (T2, 3, 4, N0 M0 S0)	29	6.8	7	3.7	4	5.1	2	3.0
Stage IS (Any T N0 M0 S1, 2, 3)	96	22.4	55	28.8	27	34.6	11	16.4
Stage II (Any T, N1, 2, 3, M0, SX, 0, 1)	8	1.9	15	7.9	4	5.1	5	7.5
Stage III (Any T, Any N, M1, 1a, SX, 0, 1,2, 3 Any T, N1, 2, 3, M0, S2, 3 Any T, Any N, M1b, Any S)	3	0.7	16	8.4	6	7.7	8	11.9

## Chart 73

### Testicular Tumours by Serum Tumour Marker A total of 984 Testicular Tumours were reported Tumour markers and Histology were reported in 426 (43.3%)

Serum Tumour Marker  Total numbers where tumour marker & histology known:	Seminoma		Teratoma		Combined Seminoma/ Teratoma		Other Histology	
	N	%	N	%	N	%	N	%
S0 (Serum marker study levels within normal limits)	158	61.7	30	31.9	15	31.9	15	53.6
S1 (LDH <1.5*N and HCG (ml/U/ml) <5,000 and AFP (ng/ml) <1,000)	79	30.9	50	53.2	25	53.2	12	42.9
S2 (LDH 1.5 – 10 *N or HCG (ml/U/ml) 5,000 - 50,000 or AFP (ng/ml) 1,000 – 10,000)	15	5.9	8	8.5	6	12.8	0	-
S3 (LDH >10*N or HCG (ml/U/ml) > 50,000 or AFP (ng/ml) >10,000)	4	1.6	6	6.4	1	2.1	1	3.6

N.B. N indicates the upper limit or normal for the LDH assay

## Chart 74

### Staging of Penile Tumours A total of 235 Penile Tumours were reported Staging could be estimated in 168 (71.5%)

Known Staging	Total Known	
	N	%
Stage 0 (Tis, a, N0 M0)	25	14.9
Stage I (T1 N0 M0)	65	38.7
Stage II (T2 N0, N1 M0)	48	28.6
Stage III (T1, 2, N2 M0 T3, N0, N1, N2, M0)	23	13.7
Stage IV (T4 Any N M0 Any T N3 M0 Any T Any N M1)	7 including 3 with metastases	4.2 1.8

## E. Initial Treatment Intention and Type

Of all the tumour sites, prostate cancer has the smallest proportion treated with curative intent. The percentage of prostate cancers treated with curative intent has increased from 28.4% in 1999 to 40% in 2002.

Radical ablative surgery for prostate cancer continues in patients with PSA levels over 50.

Laparoscopic procedures have been recorded as the initial treatment in 212 patients.


### Chart 75

#### Initial Treatment Intention by Organ Percentage & Total of Known Intent

Organ (Number Known)	Curative		Palliative		No active anti-cancer treatment		% of Total Tumours Reported
	N	%	N	%	N	%	
Prostate (13072)	5229	40.0	5799	44.4	2044	5.6	78.8
Bladder (6309)	5343	84.7	802	12.7	164	2.6	82.9
Kidney (1908)	1392	73.0	341	17.9	175	9.2	84.1
Testis (657)	646	98.3	6	0.9	5	0.8	66.8
Pelvis/Ureter (313)	259	82.7	41	13.1	13	4.2	81.9
Penis (184)	167	90.8	12	6.5	5	2.7	78.3
Urethra (20)	14	0.0	5	25.0	1	5.0	80.0
Prostatic Urethra (15)	9	60.0	5	33.3	1	6.7	78.9

## Chart 76

**Treatment Intention of Prostatic Tumours by PSA and Age**  
Percentage by PSA in each Age Group



## Chart 77

**Known Treatment Management - Kidney Tumours**  
Total Numbers Reported with those as only Treatment in ( )  
(N.B. Excluding TCC's)

Treatment	Curative	Palliative
<b>Surgery:</b>		
Endoscopic Resection	6 (5)	1 (1)
Radical Ablative Surgery	1075 (1017)	128 (67)
Organ Conserving Surgery *	56 (51)	2 (2)
Biopsy &/or Ultrasound guided biopsy	6 (1)	5 (1)
Other Surgery	16	9
Radiation Therapy	9	16 (5)
Systemic Chemotherapy	11 (2)	13 (3)
Hormone Therapy	1	7 (4)
Systemic Immunotherapy	19 (2)	59 (17)
Intravesical Immunotherapy	6 (1)	3
Palliative care	4	2
Referred to another centre / specialist	1	2
Surveillance / monitoring	1	-
Other Treatment	2	10

\* Performed by 36 centres, median per centre = 1, Range 1 -7  
126 centres performed no organ conserving surgery

## Chart 78

### Known Treatment Management - Pelvis/Ureteric Tumours Total Numbers Reported with those as only Treatment in ( )

Treatment	Curative	Palliative
<b>Surgery:</b>		
Endoscopic Resection	18 (7)	5 (3)
Endoscopic Resection + 1 shot intravesical chemotherapy	8 (5)	-
Radical Ablative Surgery	215 (193)	9 (5)
Organ Conserving Surgery	13 (7)	2 (2)
Cystoscopy	6	1 (1)
Biopsy	2	1
Other Surgery	6 (3)	-
Radiation Therapy	2	6 (4)
Systemic Chemotherapy	5 (1)	8 (5)
Hormone Therapy	-	16 (6)
Intra-vesical Chemotherapy (course)	2	1
Intra-vesical Immunotherapy (course)	3	-
Palliative care		2 (2)
Other Treatment	4	-

## Chart 79

### Known Management by T category and Grade - Bladder Tumours Total Numbers Reported with those as only Treatment in ( )

Treatment	Tis	Ta G1	Ta G2	Ta G3	T1 G1	T1 G2	T1 G3
<b>Surgery:</b>							
Endoscopic Resection	20 (6)	493 (427)	566 (474)	77 (53)	162 (143)	320 (257)	278 (162)
Endoscopic Resection + 1 shot intravesical chemotherapy	14 (5)	455 (437)	569 (536)	80 (58)	143 (139)	318 (292)	221 (142)
Radical Ablative Surgery	5 (3)	3	9 (2)	4 (3)	5 (3)	13 (8)	35 (14)
Organ Conserving Surgery	1	4	6 (1)	-	1	1 (1)	-
Biopsy / ultrasound guided biopsy	1	3 (2)	1	-	1		2 (1)
Cystoscopy	1	21 (2)	14	1	4	6	3
Other Surgery	-	-	1	-	1 (1)	-	1
Radiation Therapy	-	3 (1)	3 (1)	1	3	11 (6)	42 (4)
Systemic Chemotherapy	-	-	-	-	1	5 (2)	3 (1)
Intra-vesical Chemotherapy (course)	3 (3)	42 (2)	65 (11)	16	7	40 (2)	44 (2)
Hormone Therapy	-	1	1	-	1	3 (1)	3
Systemic Immunotherapy	8 (3)	1 (1)	3	3 (1)	1	4	13 (1)
Intra-vesical Immunotherapy (course)	21 (5)	7 (1)	16 (2)	25	4	26	77 (4)
Other Treatment	-	2	1	1	-	1	-
<b>Total Tumours Reported</b>	<b>52</b>	<b>1003</b>	<b>1168</b>	<b>163</b>	<b>316</b>	<b>673</b>	<b>541</b>



## Chart 80

**Known Management by T category and Grade - Bladder Tumours where Age is less than 70**  
Total Numbers Reported with those as only Treatment in ( )

Treatment	T2 G1	T2 G2	T2 G3	T3 G1	T3 G2	T3 G3	T4 G1	T4 G2	T4 G3
<b>Surgery:</b>									
Endoscopic Resection	-	28 (12)	107 (47)	-	3	57 (18)	3 (2)	5 (2)	45 (8)
Endoscopic Resection + 1 shot intravesical chemotherapy	5 (94)	16 (12)	29 (10)	-	1	6 (2)	-	2 (1)	5 (2)
Radical Ablative Surgery	2 (2)	16 (9)	72 (37)	-	10 (7)	65 (45)	2 (1)	5 (2)	36 (12)
Organ Conserving Surgery	-	-	3	-	-	2 (1)	-	-	-
Other Surgery	-	1	8 (3)	-	1	3	-	-	7
Radiation Therapy	1	10 (1)	41 (7)	2 (2)	4 (1)	29 (13)	1	1 (1)	33 (5)
Systemic Chemotherapy	-	3	13 (94)	-	1	18 (2)	-	4 (2)	36 (7)
Intra-vesical Chemotherapy (course)	-	2	2	-	-	2	-	2 (1)	4
Intra-vesical Immunotherapy (course)	1	1	-	-	-	3	-	-	-
Other Treatment	-	1	2	-	-	3	-	-	4 (2)
<b>Total Tumours Reported</b>	<b>7</b>	<b>60</b>	<b>200</b>	<b>2</b>	<b>14</b>	<b>131</b>	<b>5</b>	<b>15</b>	<b>98</b>

## Chart 81

**Known Management by T category and Grade - Bladder Tumours where Age >= 70**  
Total Numbers Reported with those as only Treatment in ( )

Treatment	T2 G1	T2 G2	T2 G3	T3 G1	T3 G2	T3 G3	T4 G1	T4 G2	T4 G3
<b>Surgery:</b>									
Endoscopic Resection	7 (2)	62 (30)	246 (114)	4 (1)	22 (13)	152 (59)	1 (1)	15 (8)	78 (29)
Endoscopic Resection + 1 shot intravesical chemotherapy	3 (1)	23 (10)	52 (25)	1 (1)	2 (2)	12 (4)	1	4 (1)	5 (1)
Radical Ablative Surgery	1 (1)	10 (3)	45 (23)	2 (1)	12 (7)	48 (34)	-	3 (1)	15 (4)
Organ Conserving Surgery	-	1 (1)	1 (1)	-	-	2 (2)	-	1	1 (1)
Other Surgery	-	4	5	4 (1)	1 (1)	7 (2)	-	1 (1)	3
Radiation Therapy	4	26 (6)	158 (36)	3 (1)	9 (2)	107 (23)	1 (1)	5 (1)	51 (9)
Systemic Chemotherapy	-	-	7 (1)	-	-	8 (2)	-	2	19 (2)
Intra-vesical Chemotherapy (course)	2	3	2	-	-	-	-	-	-
Hormone Therapy	1	2 (1)	1	1	-	-	-	2 (1)	1 (1)
Systemic Immunotherapy	-	-	-	-	-	1	-	-	-
Intra-vesical Immunotherapy (course)	-	1 (1)	4	-	-	2	-	-	-
Other Treatment	-	3	14 (1)	-	1	2	-	1	7 (1)
<b>Total Tumours Reported</b>	<b>11</b>	<b>106</b>	<b>397</b>	<b>8</b>	<b>40</b>	<b>243</b>	<b>2</b>	<b>23</b>	<b>119</b>

## Chart 82

**Known Management Intention - Prostate Tumours**  
**Total Numbers Reported with those as only Treatment in ( )**

Treatment	Curative	Palliative/ No active anti-cancer treatment
<b>Surgery:</b>		
<b>Endoscopic Resection</b>	321 (141)	886 (356)
<b>Radical Ablative Surgery</b>	1585 (1463)	45 (20)
<b>Organ Conserving Surgery</b>	22 (2)	51 (21)
<b>Brachytherapy</b>	133 (123)	1
<b>Biopsy</b>	37 (12)	88 (22)
<b>Ultrasound guided biopsy</b>	148 (33)	210 (44)
<b>Other Surgery</b>	9 (4)	16 (7)
<b>Radiation Therapy</b>	2424 (933)	408 (62)
<b>Systemic Chemotherapy</b>	3	7 (3)
<b>Intravesical Chemotherapy (course)</b>	10	9 (2)
<b>Hormone Therapy</b>	1838 (284)	5171 (4170)
<b>Intravesical Immunotherapy</b>	1	1
<b>Intravesical Immunotherapy (course)</b>	-	1
<b>Watchful waiting</b>	21 (9)	277 (234)
<b>Other Treatment</b>	164 (63)	232 (135)

## Chart 83

**Known Management by PSA - Prostate Tumours**  
**where age is less than 70**  
**Total Numbers Reported with those as only Treatment in ( )**

Treatment	PSA 0-5	PSA 6-10	PSA 11-15	PSA 16-20	PSA 21-50	PSA >50
<b>Surgery:</b>						
<b>Endoscopic Resection</b>	70 (44)	63 (32)	30 (12)	16 (3)	43 (10)	54 (8)
<b>Radical Ablative Surgery</b>	241 (224)	706 (664)	271 (243)	65 (55)	47 (35)	13 (11)
<b>Ultrasound guided biopsy</b>	14 (6)	47 (17)	32 (10)	14 (4)	23 (8)	20 (2)
<b>Biopsy</b>	5 (1)	12 (7)	6 (3)	5 (3)	5 (1)	10
<b>Brachytherapy</b>	16 (15)	66 (59)	19 (15)	8 (8)	1	-
<b>Other Surgery</b>	1 (1)	9 (4)	9 (4)	2 (1)	8 (2)	2 (1)
<b>Radiation Therapy</b>	108 (54)	484 (231)	288 (95)	173 (59)	315 (75)	109 (10)
<b>Systemic Chemotherapy</b>	-	1	2 (1)	-	-	1
<b>Intravesical Chemotherapy (course)</b>	1	1	2	-	2	1
<b>Hormone Therapy</b>	74 (27)	336 (83)	267 (75)	189 (62)	465 (200)	741 (574)
<b>Watchful waiting</b>	36 (30)	50 (47)	13 (10)	3 (2)	2 (2)	-
<b>Other Treatment</b>	7 (3)	15 (11)	9 (4)	6 (1)	5 (2)	7 (2)

## Chart 84

**Known Management by PSA - Prostate Tumours**  
**where age is >= 70**  
**Total Numbers Reported with those as only Treatment in ( )**

Treatment	PSA 0-5	PSA 6-10	PSA 11-15	PSA 16-20	PSA 21-50	PSA >50
<b>Surgery:</b>	<b>127 (86)</b>	<b>147 (71)</b>	<b>76 (39)</b>	<b>68 (24)</b>	<b>175 (51)</b>	<b>227 (34)</b>
<b>Endoscopic Resection</b>						
<b>Radical Ablative Surgery</b>	22 (16)	79 (74)	48 (39)	11 (9)	12 (6)	21 (8)
<b>Ultrasound guided biopsy</b>	11 (5)	48 (22)	35 (12)	35 (10)	72 (15)	64 (3)
<b>Biopsy</b>	9 (5)	11 (7)	6 (4)	11 (3)	24 (4)	36 (4)
<b>Brachytherapy</b>	2 (2)	11 (10)	6 (6)	2 (2)	1 (1)	-
<b>Other Surgery</b>	3	4 (2)	2 (1)	4 (4)	14 (4)	4 (2)
<b>Radiation Therapy</b>	65 (27)	292 (110)	258 (88)	189 (62)	237 (60)	82 (17)
<b>Systemic Chemotherapy</b>	1	-	-	-	3 (1)	-
<b>Intravesical Chemotherapy (course)</b>	1 (1)	4	1	1	5	1
<b>Hormone Therapy</b>	107 (49)	466 (238)	533 (325)	518 (331)	1458 (1100)	2023 (1674)
<b>Watchful waiting</b>	34 (22)	59 (44)	41 (32)	26 (24)	23 (19)	7 (6)
<b>Other Treatment</b>	7 (2)	21 (7)	13 (7)	9 (6)	13 (5)	8

## Chart 85

**Known Management - Testicular Tumours**  
**Total Numbers Reported with those as only Treatment in ( )**

Treatment	Curative	Palliative
<b>Radical Ablative Surgery</b>	614 (298)	3 (1)
<b>Organ Conserving Surgery</b>	3 (2)	-
<b>Other Surgery</b>	8 (1)	-
<b>Radiation Therapy</b>	149 (7)	-
<b>Systemic Chemotherapy</b>	165 (7)	4 (2)
<b>Other Treatment</b>	24 (1)	-

## Chart 86

**Known Management - Penile Tumours**  
**Total Numbers Reported with those as only Treatment in ( )**

Treatment	Curative	Palliative
<b>Surgery:</b>		
<b>Radical Ablative Surgery</b>	<b>54 (47)</b>	<b>5 (2)</b>
<b>Organ Conserving Surgery</b>	<b>89 (81)</b>	<b>3 (2)</b>
<b>Other Surgery</b>	<b>14 (5)</b>	<b>4 (20)</b>
<b>Radiation Therapy</b>	<b>11 (4)</b>	<b>2</b>
<b>Other Treatment</b>	<b>6 (3)</b>	<b>-</b>

## Chart 87

### Laparoscopic Procedures Performed

Number of tumours recorded as being operated on laparoscopically = 212

Organ	Procedure and Number Reported	Organ	Procedure and Number Reported
<b>Prostate</b> <b>104 total</b>	9 Radical prostatectomies 3 Lymph node sampling/staging 92 Procedure not recorded	<b>Kidney</b> <b>77 total</b>	42 Nephrectomy 3 Nephroureterectomy 1 Partial Nephrectomy 31 Procedure not recorded
<b>Bladder</b> <b>4 total</b>	1 Insertion of JJ stent 3 Procedure not recorded	<b>Pelvis/Ureter</b> <b>27 total</b>	11 Nephroureterectomy 16 Procedure not recorded

## Chart 88

### Laparoscopic Surgery by Organ and Stage

Number of tumours recorded as being operated on laparoscopically = 212

Staging	Prostate N	Bladder N	Kidney N	Pelvis/Ureter N
Stage 0a	N/A	1	N/A	11
Stage I	-	-	56	3
Stage II	91	1	10	4
Stage III	12	1	4	5
Stage IV	1	-	3	1
Not Recorded	-	1	4	3
<b>Totals</b>	<b>104</b>	<b>4</b>	<b>77</b>	<b>27</b>

## F. Tertiary Referrals

A greater percentage (8.0%) of all registrations in 2002 were tertiary referrals than in 2001 (4.4%), primarily due to the inclusion of returns from one major tertiary referral centre.

### Chart 89

**Tertiary Referrals - Overall Data by Organ**  
**8.0% (2267/28351) of all tumours were tertiary referrals**  
**(referred by a Urologist (2155) or Oncologist (112))**

Organ	Number Recorded	Mean Age at Diagnosis & Range	Males	Females	* % of Total Registrations	** % of Total Registrations in 2001
Prostate	1444	66.5; 37 – 94	1444	-	8.7	5.0
Bladder	254	70.3; 40 – 92	197	55	2.1	2.1
Kidney	210	63.3; 26 – 68	141	68	9.3	6.0
Testis	80	39.8; 16 – 79	80	-	8.1	5.9
Pelvis/Ureter	34	70.2; 41 – 85	25	9	8.9	9.2
Penis	37	63.5; 41 – 89	37	-	15.7	9.2
Urethra	4	63; 55 – 69	4	-	16.0	8.1
Prostatic Urethra	3	82.7; 81 – 86	3	-	15.8	10.5
Other	4	68; 62 – 72	2	2	6.0	8.1
Not recorded	2	77; 77 – 77	2	-	1.1	2.6

\* % of the total registrations for each tumour site e.g. prostate = 1444/16580 = 8.7%

\*\* Equivalent figures recorded for diagnoses in 2001

## G. Clinical Trial Status

This was a new field for 2002 but has been poorly completed with some 46% of the returns not including the information and a further 17% where the clinical trial status was unknown

### Chart 90

#### **Clinical Trial Status** Status was reported in 54.5% of cases (15454 / 28351 )

<b>Trial Status</b>	<b>N</b>	<b>%</b>
<b>Patient eligible, consented to and entered trial</b>	<b>597</b>	<b>2.1</b>
<b>Patient eligible for trial but declined entry</b>	<b>144</b>	<b>0.5</b>
<b>Patient ineligible for trial</b>	<b>1088</b>	<b>3.8</b>
<b>Patient not considered for trial</b>	<b>8746</b>	<b>30.8</b>
<b>Clinical trial status unknown</b>	<b>4879</b>	<b>17.2</b>
<b>Not Recorded</b>	<b>12897</b>	<b>45.5</b>

## H. Completeness of Data

The trends are favourable. The recording of NHS number remains a problem and has implications for matching our data to that of other cancer registries.

### Chart 91

**Completeness of Data -1**  
**Percentage and numbers of Total Returns unknown**

Data Item	2002 Number Unknown	% of Total Returns 28351	2001 Number Unknown	% of Total Returns 26746	2000 Number Unknown	% of Total Returns 24343
Centre no or Cons no	0	0	0	0	0	0
Hospital number	*499	1.8	**469	1.8	***577	2.4
NHS number	8801	31.0	9620	36.0	8580	35.2
Postcode	1769	6.2	1525	5.7	1573	6.5
Sex	78	0.3	78	0.3	39	0.2
Date of Birth	159	0.6	193	0.7	192	0.8
Organ	177	0.6	189	0.7	136	0.6
Date of Diagnosis	551	1.9	462	1.7	466	1.9
Referral Source	2087	7.4	1892	7.1	2058	8.5
Priority of GP Referrals	1172/19893	5.9	2356/20023	11.8	-	-
Date of Referral	3436	12.1	3057	11.4	2931	12.0
Date of First Consultation	2286	8.1	2641	9.9	3205	13.2
Date of Definitive Treatment	10071	35.5	11996	44.9	-	-
Histological confirmation	1626	5.7	1044	3.9	483	2.0
Basis of diagnosis if no Histology	131/1484	8.8	112/1279	8.8	111/1233	9.0

includes private patients, \* = 385 \*\* = 326; \*\*\* = 349

### Chart 92

**Completeness of Data -2**  
**Percentage and numbers of Total Returns unknown**

Data Item	2002 Number Unknown	% of Total Returns 28351	2001 Number Unknown	% of Total Returns 26746	2000 Number Unknown	% of Total Returns 24343
Histology	834/25241	3.3	297/24422	1.2	261/22627	1.2
Differentiation	4551/25241	16.1	3176/24422	13.0	2690/22627	11.9
Clinical T Category	1876	6.6	1933	7.2	3835	15.8
Clinical N Category	4430	15.6	4514	16.9	6244	25.7
Clinical M Category	3881	13.7	4502	16.8	6273	25.8
Pathological T Category	1228/5482	22.4	897/7916*	11.3	7175/22627	31.7
Pathological N Category	1443/5482	26.3	1663/7916*	21.0	9703/22627	43.0
Pathological M Category	1477/5482	26.9	1739/7916*	22.0	9793/22627	43.3
PSA at time of Diagnosis	2086/16580	12.6	1356/15099	9.0	1361/12892	10.6
Gleason Scores	2112/16580	7.4	2364/15099	15.7	2495/12892	19.4
S Category	558/984	56.7	403/963	41.8	338/980	34.5
Treatment Intention	5759	20.3	4201	15.7	3067	12.6
Treatment Type	975/20133	4.8	623/20223	3.1	567/19299	2.9
Clinical Trial Status	12897	45.5	-	-	-	-

\* A pathological staging for Stage II, III or IV bladder tumours and all prostate tumours was only expected where radical surgery was performed. For kidney & pelvis/ureteric tumours it was only expected for those where radical or organ conserving surgery was performed.



## Appendix

### Regional and district health authorities 1998 & 1999:

Source: Registrations of Cancer diagnoses in 1998, England, series MB1 no 29 (ISBN 1-85774 4837)

Registrations of Cancer diagnoses in 1999, England, series MB1 no30 (ISBN 1-85774 5361)

### Regional and district health authorities (1998)

#### Northern and Yorkshire

Bradford  
County Durham  
East Riding  
Gateshead and South  
Tyneside  
Leeds  
Newcastle and North  
Tyneside  
North Cumbria  
Northumberland  
Sunderland  
Tees  
Wakefield  
North Yorkshire  
Calderdale and Kirklees

#### Trent

Barnsley  
North Derbyshire  
Southern Derbyshire  
Doncaster  
Leicestershire  
Lincolnshire  
North Nottinghamshire  
Nottingham  
Rotherham  
Sheffield  
South Humber

#### Anglia and Oxford

Bedfordshire  
Berkshire  
Buckinghamshire  
Cambridge and  
Huntingdon  
East Norfolk  
Northamptonshire  
North West Anglia  
Oxfordshire  
Suffolk

#### North Thames

Barking and Havering  
Barnet

Brent and Harrow  
Camden and Islington  
Ealing, Hammersmith  
and Hounslow  
East London and the City  
Enfield and Haringey  
North Essex  
South Essex  
West Hertfordshire  
East and North  
Hertfordshire  
Hillingdon  
Kensington, Chelsea  
and Westminster  
Redbridge and  
Waltham Forest

#### South Thames

Bexley and Greenwich  
Bromley  
Croydon  
East Kent  
West Kent  
Kingston and Richmond  
Lambeth, Southwark and  
Lewisham  
Merton, Sutton  
and Wandsworth  
East Surrey  
West Surrey  
East Sussex, Brighton and  
Hove  
West Sussex

#### South and West

Cornwall and Isles of  
Scilly  
Dorset  
North and East Devon  
Gloucestershire  
North and Mid  
Hampshire  
Portsmouth and South  
East Hampshire

Southampton and South  
West Hampshire  
Isle of Wight (unitary  
authority)  
Somerset  
South and West Devon  
Wiltshire  
Avon

#### West Midlands

Birmingham  
Coventry  
Dudley  
Herefordshire  
Sandwell  
Shropshire  
Solihull  
North Staffordshire  
South Staffordshire  
Walsall  
Warwickshire  
Wolverhampton  
Worcestershire

#### North West

Bury and Rochdale  
North Cheshire  
South Cheshire  
East Lancashire  
North West Lancashire  
South Lancashire  
Liverpool  
Manchester  
Morecambe Bay  
St Helen's and Knowsley  
Salford and Trafford  
Sefton  
Stockport  
West Pennine  
Wigan and Bolton  
Wirral

## Regional and district health authorities (1999)

### **Northern and Yorkshire**

Bradford  
County Durham  
East Riding  
Gateshead and South  
Tyneside  
Leeds  
Newcastle and North  
Tyneside  
North Cumbria  
Northumberland  
Sunderland  
Tees  
Wakefield  
North Yorkshire  
Calderdale and Kirklees

### **Trent**

Barnsley  
North Derbyshire  
Southern Derbyshire  
Doncaster  
Leicestershire  
Lincolnshire  
North Nottinghamshire  
Nottingham  
Rotherham  
Sheffield  
South Humber

### **Eastern**

North Essex  
South Essex  
Bedfordshire  
Suffolk  
East and North  
Hertfordshire  
West Hertfordshire  
Cambridgeshire  
Norfolk

### **London**

Bexley and Greenwich

Barking and Havering  
Barnet  
Brent and Harrow  
Camden and Islington  
Ealing, Hammersmith  
and Hounslow  
East London and the City  
Enfield and Haringey  
Bromley  
Croydon  
Kingston and Richmond  
Lambeth, Southwark and  
Lewisham  
Hillingdon  
Kensington, Chelsea  
and Westminster  
Redbridge and  
Waltham Forest  
Merton, Sutton and  
Wandsworth  
**South East**  
East Kent  
West Kent  
East Surrey  
West Surrey  
East Sussex, Brighton and  
Hove  
West Sussex  
Berkshire  
Buckinghamshire  
Northamptonshire  
Oxfordshire  
North and Mid Hampshire  
Portsmouth and South  
East Hampshire  
Southampton and South  
West Hampshire  
Isle of Wight  
**South West**  
Cornwall and Isles of

Scilly  
Dorset  
North and East Devon  
Gloucestershire  
Somerset  
South and West Devon  
Wiltshire  
Avon  
**West Midlands**  
Birmingham  
Coventry  
Dudley  
Herefordshire  
Sandwell  
Shropshire  
Solihull  
North Staffordshire  
South Staffordshire  
Walsall  
Warwickshire  
Wolverhampton  
Worcestershire  
**North West**  
Bury and Rochdale  
North Cheshire  
South Cheshire  
East Lancashire  
North West Lancashire  
South Lancashire  
Liverpool  
Manchester  
Morecambe Bay  
St Helen's and Knowsley  
Salford and Trafford  
Sefton  
Stockport  
West Pennine  
Wigan and Bolton  
Wirral